Dyne Therapeutics, Inc. announced yesterday the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.
The IND submission for DYNE-251 represents a significant milestone. Dyne expects to begin dosing patients in clinical trials for DMD by mid-year 2022.
The IND application for DYNE-251 includes data from recent studies in the mdx mouse and in non-human primates, and outlines plans for a global, randomized, placebo controlled, multiple ascending dose (MAD) clinical trial with a long term extension study. The Phase 1/2 trial aims to enroll approximately 30 to 40 ambulant and non-ambulant male patients ages 4 to 16 with mutations amenable to exon 51 skipping therapy. Planned endpoints include safety and tolerability, PK/PD, dystrophin expression as measured by Western Blot, and measures of muscle function.
In addition to DYNE-251, Dyne is developing a DMD franchise with programs for patients with mutations amenable to skipping exons 53, 45 and 44.
For the full release click here.